HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Margetuximab Improves PFS in Metastatic HER2+ Breast Cancer

February 7th 2019

Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.

FDA Approval Sought for Adjuvant T-DM1 in High-Risk HER2+ Breast Cancer

February 5th 2019

Genentech has completed its FDA submission of a supplemental Biologics License Application for ado-trastuzumab emtansine as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy.

Dr. Burris Discusses Promise of T-DM1 in HER2+ Breast Cancer

February 5th 2019

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the promise of T-DM1 in the treatment of patients with HER2-positive breast cancer.

New Findings Expand Options in Early HER2-Positive Breast Cancer

February 4th 2019

During a recent OncLive Peer Exchange®, panel members discussed the use of HER2-targeted therapies in patients with early-stage HER2-positive breast cancer in the neoadjuvant and adjuvant settings.

Dr. Hamilton on Adjuvant Therapy for HER2+ Breast Cancer

February 2nd 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

Expert Expects T-DM1 to Transform Treatment in HER2+ Breast Cancer

January 29th 2019

Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.

SABCS 2018 Showcased Practice-Changing Advances in Breast Cancer

January 25th 2019

Stephen C. Malamud, MD, reflects on the intriguing and practice-changing data presented at the 2018 SABCS.

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer

January 25th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the role of pertuzumab in HER2-positive breast cancer.

Dr. Geyer on Impact of Targeted Agents in HER2+ Breast Cancer

January 22nd 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast Cancer

January 19th 2019

Mothaffar F. Rimawi, MD, an associate professor and director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the KATHERINE trial in HER2-positive breast cancer.

Dr. Shao on Managing Toxicity With Neratinib in HER2+ Breast Cancer

January 16th 2019

Theresa Shao, MD, assistant professor of medicine, hematology and medical oncology, Icahn School of Medicine, Mount Sinai Medical Center, discusses managing toxicities associated with neratinib (Nerlynx) in patients with HER2-positive breast cancer.

Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer

January 15th 2019

Mothaffar F. Rimawi, MD, discusses the current options in HER2-positive breast cancer and sheds light on where future research is headed.

Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer

January 7th 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.

Drugs Make Progress in Breaching the Blood-Brain Barrier

January 4th 2019

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

Dr. Rimawi Discusses Role of TKIs in HER2+ Breast Cancer

January 3rd 2019

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the role of TKIs in the treatment of HER2-positive breast cancer.

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

December 29th 2018

Trastuzumab ADCC May Affect Outcomes in HER2+ Breast Cancer

December 28th 2018

Patients with HER2-positive early or locally advanced breast cancer who were exposed to reference trastuzumab lots with a marked downward shift in antibody-dependent cell-mediated cytotoxicity (ADCC) had worse outcomes than those not exposed to at least 1 shifted ADCC lot or those treated with its biosimilar.

Dr. Tripathy Discusses Pertuzumab in HER2+ Breast Cancer

December 21st 2018

Neratinib Improves PFS in HER2+ Metastatic Breast Cancer

December 19th 2018

Neratinib led to a statistically significant improvement in centrally confirmed progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy.

De-Escalation Possible in Curative Setting for HER2+ Breast Cancer

December 18th 2018

Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.